BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

12015 related articles for article (PubMed ID: 12107381)

  • 1. Clinical oncological applications of Positron Emission Tomography (PET) using fluorine-18-fluoro-2-deoxy-D-glucose.
    Giorgetti A; Volterrani D; Mariani G
    Radiol Med; 2002 Apr; 103(4):293-318. PubMed ID: 12107381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.
    Antoch G; Saoudi N; Kuehl H; Dahmen G; Mueller SP; Beyer T; Bockisch A; Debatin JF; Freudenberg LS
    J Clin Oncol; 2004 Nov; 22(21):4357-68. PubMed ID: 15514377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Imaging of cancer using positron emission tomography].
    Goldman S; Vanderhoeft A; Lebeau de Hemricourt E; Dusart M; Damhaut P; Wikler D
    Rev Med Brux; 1999 Sep; 20(4):A365-8. PubMed ID: 10523925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET FDG studies in oncology.
    Hawkins RA; Hoh CK
    Nucl Med Biol; 1994 Jul; 21(5):739-47. PubMed ID: 9241650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [18F] 3-deoxy-3'-fluorothymidine positron emission tomography: alternative or diagnostic adjunct to 2-[18f]-fluoro-2-deoxy-D-glucose positron emission tomography in the workup of suspicious central focal lesions?
    Halter G; Buck AK; Schirrmeister H; Wurziger I; Liewald F; Glatting G; Neumaier B; Sunder-Plassmann L; Reske SN; Hetzel M
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1093-9. PubMed ID: 15052207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of positron emission tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory oncology.
    Vansteenkiste JF; Stroobants SG
    Eur Respir J; 2001 Apr; 17(4):802-20. PubMed ID: 11401078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical role of FDG PET in evaluation of cancer patients.
    Kostakoglu L; Agress H; Goldsmith SJ
    Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000.
    Reske SN; Kotzerke J
    Eur J Nucl Med; 2001 Nov; 28(11):1707-23. PubMed ID: 11702115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positron emission tomography: clinical applications in oncology. Part 1.
    Kumar R; Nadig MR; Chauhan A
    Expert Rev Anticancer Ther; 2005 Dec; 5(6):1079-94. PubMed ID: 16336099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical applications of FDG-PET in oncology.
    Czernin J
    Acta Med Austriaca; 2002; 29(5):162-70. PubMed ID: 12506767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG PET/CT in oncology: "raising the bar".
    Patel CN; Goldstone AR; Chowdhury FU; Scarsbrook AF
    Clin Radiol; 2010 Jul; 65(7):522-35. PubMed ID: 20541652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F FDG PET- applications in oncology].
    Răileanu I; Rusu V; Stefănescu C; Cinotti L
    Rev Med Chir Soc Med Nat Iasi; 2001; 105(4):638-45. PubMed ID: 12092212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The value of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET) in diagnosis of neoplastic diseases].
    Ruiz Hernández G; Romero de Avila Y Avalos C; Carreras Delgado JL
    Med Clin (Barc); 2005 Feb; 124(6):229-36. PubMed ID: 15737307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical usefulness of FDG-PET in oncology].
    Sasaki M
    Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Appropriate use of positron emission tomography with [(18)F]fluorodeoxyglucose for staging of oncology patients.
    Tagliabue L; Del Sole A
    Eur J Intern Med; 2014 Jan; 25(1):6-11. PubMed ID: 23910561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology].
    Maublant J; Vuillez JP; Talbot JN; Lumbroso J; Muratet JP; Herry JY; Artus JC
    Bull Cancer; 1998 Nov; 85(11):935-50. PubMed ID: 9951421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual-head gamma camera 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in oncological patients: effects of non-uniform attenuation correction on lesion detection.
    Zimny M; Kaiser HJ; Cremerius U; Reinartz P; Schreckenberger M; Sabri O; Buell U
    Eur J Nucl Med; 1999 Aug; 26(8):818-23. PubMed ID: 10436193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
    Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
    Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Positron emission tomography imaging in evaluation of cancer patients.
    Kumar R; Bhargava P; Bozkurt MF; Zhuang H; Potenta S; Alavi A
    Indian J Cancer; 2003; 40(3):87-100. PubMed ID: 14716112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical role of positron emission tomography in oncology.
    Bomanji JB; Costa DC; Ell PJ
    Lancet Oncol; 2001 Mar; 2(3):157-64. PubMed ID: 11902566
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 601.